Tayal Vandana, Kalra Bhupinder Singh
Department of Pharmacology, Maulana Azad Medical College, Bahadur Shah Zafar Marg, Delhi, India.
Indian Heart J. 2008 Jan-Feb;60(1):69-72.
Hypertension is one of the major causes of cardiovascular morbidity. Most patients who are on treatment for hypertension fail to achieve adequate control with the existing therapy and rates of cardiovascular morbidity remain high. As the renin-angiotensin-aldosterone system is strongly implicated in the development of hypertension-related target organ damage, intensive efforts have been devoted towards the development of drugs targeting this system. In addition to angiotensin converting enzyme inhibitors and angiotensin receptor blockers, inhibition of renin has also become a clinical reality. Aliskiren, a novel renin inhibitor, has overcome a number of shortcomings of existing drugs and is now available to address angiotensin production directly at its rate-limiting step.
高血压是心血管疾病发病的主要原因之一。大多数接受高血压治疗的患者无法通过现有疗法实现充分控制，心血管疾病的发病率仍然很高。由于肾素-血管紧张素-醛固酮系统与高血压相关靶器官损害的发生密切相关，人们一直在大力研发针对该系统的药物。除了血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂外，抑制肾素也已成为临床现实。阿利吉仑是一种新型肾素抑制剂，克服了现有药物的许多缺点，现在可直接在限速步骤解决血管紧张素的产生问题。
